Cardiocomm Solutions Appoints Industry Veteran As Vp Sales And Marketing To Build U.S. Based Patient Monitoring Software And ...
08 Janvier 2014 - 5:00PM
Access Wire
Former Executive of
ScottCare, CardioNet and Lifewatch Corporation Set to Drive Sales
of GEMS(TM) and Mobile Patient Monitoring Solutions into the U.S.
Market
TORONTO, ONTARIO - CardioComm Solutions, Inc.
(TSX VENTURE:EKG) ("CardioComm
Solutions" or the "Company") today announced that Mr. Daniel Pawlik
has joined the organization as Vice President, Sales and Marketing
for the United States effective January 6, 2014.
Mr. Pawlik has held senior executive
positions within a number of large U.S.-based companies
specializing in electrocardiogram ("ECG") cardiac monitoring
including Vice President of Sales, Marketing and Business
Development U.S. Diagnostic Field Sales, Technologies and Contract
Services for Ambucor Health Solutions, Inc., a subsidiary of
ScottCare Corporation, and Vice President, Research Services and
Technologies at LifeWatch Services Inc.
Pawlik was the Founder and CEO of Agility
Centralized Research Services, Inc., a clinical
research-based patient
monitoring center providing telemedicine technology and operational
outsourcing of patient monitoring for cardiac safety testing,
contract project management, data collection and analysis to the
pharmaceutical, medical device and academic research community.
Agility Research was acquired initially by Biotel and is now a
wholly owned subsidiary of Philadelphia based CardioNet, Inc. where
Pawlik served as Vice President, Research Services Agility
Centralized Research Services until recruited by ScottCare
Corporation.
"Dan
Pawlik is a welcome addition to the CardioComm Solutions team,"
noted Simi Grosman, a member of the Company's Board of Directors.
"His knowledge of the cardiac monitoring landscape in the U.S. will
allow us to accelerate our sales and development activities in 2014
and become a key player in this market. We will continue to build
out the U.S. team under his leadership."
CardioComm Solutions' entry into the mobile
cardiac telemetry ("MCT") market was announced last year when it
concluded a device integration and distribution deal with TZ
Medical that brought the two companies into the MCT ECG and
arrhythmia management market. Recently the Company announced
completion of a custom MCT solution for Raytel Cardiac Monitoring,
heralding the release of an off-the-shelf MCT software solution
anticipated for early 2014.
In
addition to adding bench strength to CardioComm Solutions'
management team, Daniel will be directly responsible for driving
sales of GEMS(TM) and patient monitoring solutions in the U.S. The
cardiac monitoring and cardiac rhythm management devices market is
expected to grow to $23.3B over the next three years according to a
report by MarketsandMarkets, a global market research and
consulting company based in the U.S. Pawlik will also leverage his
extensive network to identify HeartCheck(TM) PEN
over-the-counter (OTC) sales
and service opportunities in the U.S. market.
"I am very pleased
and excited to be joining the CardioComm Solutions' leadership team
in their mission to build presence and grow market share within the
U.S. health care market. CardioComm Solutions has developed an
extremely innovative, flexible and effective patient monitoring and
data management system in the GEMS(TM) software technology
platform. The GEMS(TM) technology design and the capability of the
Company's development team will enable our introduction of a
considerable number of innovative sales and service solutions that
will help providers lower clinical costs, improve operational
efficiencies and patient care while increasing service revenues,"
said Daniel Pawlik. "I am confident CardioComm Solutions will be a
welcomed technology partner to many health care organizations."
"We are very
pleased to welcome Dan to the CardioComm Solutions team," said
Etienne Grima, CardioComm Solutions' CEO. "Dan has over 20 years of
experience in the medical device and clinical research industry
where he was responsible for the restructure of sales,
marketing and business development operations, the integration of
contract research services and development of large sales forces to
support business expansion across the United States. Dan's
priorities will include driving the launch of our
GEMS(TM) 4 product and MCT software as well as to assist in
establishing new technology and service revenue streams from
strategic partnerships with independent diagnostic testing
facilities, health care providers and increasing HeartCheck(TM)
related service revenues."
About CardioComm Solutions
CardioComm Solutions' patented and
proprietary technology is used in products for recording, viewing,
analyzing and storing electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products are sold worldwide through
a combination of an external distribution network and a North
American-based sales team. The Company has earned the ISO 13485
certification, is HPB approved, HIPAA compliant, and has received
FDA market clearance for its software devices. CardioComm Solutions
is headquartered in Toronto, Canada, with offices in Victoria,
B.C.
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com
http://www.theheartcheck.com/
Forward-looking statements
This release may contain certain
forward-looking statements with respect to the financial condition,
results of operations and business of CardioComm Solutions and
certain of the plans and objectives of CardioComm Solutions with
respect to these items. By their nature, forward-looking statements
involve risk and uncertainty because they relate to events and
depend on circumstances that will occur in the future and there are
many factors that could cause actual results and developments to
differ materially from those expressed or implied by these
forward-looking statements.
Neither TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
CardioComm Solutions (TSXV:EKG)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
CardioComm Solutions (TSXV:EKG)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024